GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gemina Laboratories Ltd (XCNQ:GLAB) » Definitions » EBITDA Margin %

Gemina Laboratories (XCNQ:GLAB) EBITDA Margin % : 0.00% (As of Jan. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gemina Laboratories EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gemina Laboratories's EBITDA for the three months ended in Jan. 2024 was C$-1.01 Mil. Gemina Laboratories's Revenue for the three months ended in Jan. 2024 was C$0.00 Mil. Therefore, Gemina Laboratories's EBITDA margin for the quarter that ended in Jan. 2024 was 0.00%.


Gemina Laboratories EBITDA Margin % Historical Data

The historical data trend for Gemina Laboratories's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gemina Laboratories EBITDA Margin % Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24
EBITDA Margin %
- - - -

Gemina Laboratories Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Gemina Laboratories's EBITDA Margin %

For the Biotechnology subindustry, Gemina Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gemina Laboratories's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's EBITDA Margin % falls into.



Gemina Laboratories EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Gemina Laboratories's EBITDA Margin % for the fiscal year that ended in Jan. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Jan. 2024 )/Revenue (A: Jan. 2024 )
=-5.104/0
= %

Gemina Laboratories's EBITDA Margin % for the quarter that ended in Jan. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jan. 2024 )/Revenue (Q: Jan. 2024 )
=-1.012/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gemina Laboratories  (XCNQ:GLAB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Gemina Laboratories EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Gemina Laboratories's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gemina Laboratories (XCNQ:GLAB) Business Description

Traded in Other Exchanges
Address
3800 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.
Executives
James Damian Tansey Director

Gemina Laboratories (XCNQ:GLAB) Headlines

No Headlines